<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850016</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0896</org_study_id>
    <nct_id>NCT02850016</nct_id>
  </id_info>
  <brief_title>Romidepsin Plus 3BNC117 Phase 2a Study</brief_title>
  <acronym>ROADMAP</acronym>
  <official_title>A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin&#xD;
      alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals&#xD;
      during an analytical interruption of ART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized interventional phase 2a trial of 3BNC117 and romidepsin in human&#xD;
      immunodeficiency (HIV-1) infected patients on ART, conducted as a multi-center study at the&#xD;
      Department of Infectious Diseases, Aarhus University Hospital, Denmark, the Rockefeller&#xD;
      University Hospital, USA, and the University Hospital of Cologne, Germany.&#xD;
&#xD;
      Participants will be randomized 1:1 in a non-blinded fashion to receive one of two regimens:&#xD;
&#xD;
      A) Two treatment cycles each consisting of one 3BNC117 infusion (30mg/kg) + three romidepsin&#xD;
      infusions (5mg/m2); or&#xD;
&#xD;
      B) Two treatment cycles each consisting of three romidepsin infusions (5mg/m2).&#xD;
&#xD;
      ART will be discontinued 16 weeks after the start of the second treatment cycle (analytical&#xD;
      treatment interruption, ATI) and subjects will be monitored weekly for safety and viral&#xD;
      rebound. The targeted enrollment is 30 subjects (15 per arm).&#xD;
&#xD;
      Leukapheresis will be performed before and after the two treatment cycles to guarantee&#xD;
      sufficient material to investigate changes in the reservoir after the interventions.&#xD;
&#xD;
      The following criteria will require resumption of ART:&#xD;
&#xD;
        -  CD4+ T cell-count &lt;350 cells/mm³ (confirmed by repeat measurement)&#xD;
&#xD;
        -  2 consecutive plasma HIV-1 RNA measurements ≥ 200 copies/mL or above their setpoint&#xD;
           viremia (if documented)&#xD;
&#xD;
        -  Subject request&#xD;
&#xD;
        -  Continued ART interruption will, in the opinion of the investigator or study advisers,&#xD;
           pose an unacceptable risk to the subject.&#xD;
&#xD;
      If HIV-1 RNA remains undetectable at week 36, subjects will be offered to continue off ART&#xD;
      with close monitoring, in conjunction with the subject's primary medical provider, as long as&#xD;
      HIV-1 viral rebound does not occur. ART resumption will follow same criteria as detailed&#xD;
      above. All subjects will be followed for a total of 48 weeks from enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to viral rebound during analytical treatment interruption (ATI)</measure>
    <time_frame>Week 24 to Week 36</time_frame>
    <description>Viral rebound is defined as HIV-1 RNA ≥ 200 copies/mL on 2 consecutive measurements during ATI. If viral rebound occurs, the date of the first measurement of HIV-1 RNA ≥ 200 copies/mL will be defined as &quot;date of viral rebound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days to reinitiation of ART in participants who restart ART before viral rebound.</measure>
    <time_frame>Week 24 to Week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of of adverse events (AE), serious adverse events (SAE), and serious unexpected serious adverse reactions (SUSAR).</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of the functional, latent HIV-1 reservoir</measure>
    <time_frame>Day -14 and Day 154</time_frame>
    <description>As determined by the number of infectious units per 106 resting memory CD4+ T cells (IUPM) using a viral outgrowth assay before and after therapy. Post therapy measurements will occur after the second cycle, just before ATI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of the proviral HIV-1 reservoir</measure>
    <time_frame>48 weeks</time_frame>
    <description>Determined by total HIV-1 DNA and episomal HIV-1 DNA (2-LTR) in circulating total CD4+ T cells at baseline, after each romidepsin cycle, prior to the ATI period (week 24), and at the end of the study (week 48).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA</measure>
    <time_frame>48 weeks</time_frame>
    <description>As measured by a routine clinical assay (Cobas Taqman; detection limit 20 copies/mL), a transcription mediated amplification (TMA)-based assay (detection limit 12 copies/ml) and/or a single copy assay (detection limit 1-2 copies/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV-1 transcriptional activity as determined by unspliced HIV-1 RNA in circulating total CD4+ T cells.</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phylogenetically compare viruses grown from PBMCs collected from participants while on ART to rebound viruses collected after ART interruption.</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma cytokine and immune activation biomarker levels.</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the capacity of NK and CD8+ T cells to mediate inhibition of viral replication ex vivo.</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Absolute cell counts T and NK cells</measure>
    <time_frame>48 weeks</time_frame>
    <description>using standard cell marker panels by flow cytometry (e.g. CD3, CD4, CD8, CD45RA, CCR7 for T cells and CD16/CD56 for NK cells).</description>
  </other_outcome>
  <other_outcome>
    <measure>Phenotypic characteristics for T and NK cells</measure>
    <time_frame>48 weeks</time_frame>
    <description>Functional properties of cytotoxic T cells and NK cells will be investigated by analyzing cytokine secretion properties (e.g. IL-2, IFN-γ, TNF-α) and surface expression of CD107a/b as a surrogate marker of cytotoxic activities. CD69, CD161, NKp46, NKG2, and CD85J expression will be analysed on NK cells.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>Intravenous Infusion of 3BNC117</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Monoclonal Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Intravenous Infusion of Romidepsin</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>HDAC inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age 18-65 years with documented HIV-1 infection&#xD;
&#xD;
          -  CD4+ T-cell count &gt;500 cells/mm3 at screening&#xD;
&#xD;
          -  On ART for a minimum of 24 months and HIV-1 RNA plasma level of &lt; 50 copies/ml by&#xD;
             standard assays for at least 18 months (a single viral load measurement &gt; 50 but &lt; 500&#xD;
             copies/ml during this time period is allowable).&#xD;
&#xD;
          -  Individuals on protease inhibitor or NNRTI-based regimens, or regimens containing&#xD;
             cobicistat must be willing to switch to an integrase-inhibitor-based regimen&#xD;
             (raltegravir or dolutegravir) prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications&#xD;
             considered significant by the investigators within the last 6 months&#xD;
&#xD;
          -  Pregnancy as determined by a positive urine or serum beta-hCG.&#xD;
&#xD;
          -  Participant unwilling to use two reliable contraception methods (i.e. condom with&#xD;
             spermicide, diaphragm with spermicide, progestin-only containing intrauterine device&#xD;
             (IUD) (eg, Mirena, Implanon, Nuva Ring), non-estrogen containing formulations of&#xD;
             hormonal birth control drugs with condom) for the study duration.&#xD;
&#xD;
          -  Currently breast-feeding.&#xD;
&#xD;
          -  History of resistance to 2 or more classes of antiretroviral medications&#xD;
&#xD;
          -  Any medical, psychiatric, social, or occupational condition that, as judged by the&#xD;
             investigators, would interfere with the evaluation of study objectives (such as severe&#xD;
             alcohol or drug abuse, dementia).&#xD;
&#xD;
          -  Acute or chronic hepatitis B or C infection as indicated by the presence of Hepatitis&#xD;
             B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.&#xD;
&#xD;
          -  A history of AIDS-defining illness within 3 years prior to enrollment.&#xD;
&#xD;
          -  History of B-cell lymphoma, including CNS lymphoma&#xD;
&#xD;
          -  CD4 nadir &lt; 200 cells/mm3&#xD;
&#xD;
          -  History of significant coronary artery disease, myocardial infarction, percutaneous&#xD;
             coronary intervention with placement of cardiac stents, or family history of sudden&#xD;
             death at age &lt; 50 years.&#xD;
&#xD;
          -  ECG at screening that shows QTc &gt;450 msec when calculated using the Fridericia formula&#xD;
             from either lead V3 or V4, pathological Q-waves (Q-wave &gt; 40 msec or depth &gt; 0.4-0.5&#xD;
             mV), evidence of a ventricular pre-excitation syndromes, complete or incomplete LBBB&#xD;
             or RBBB, second or third degree heart block, QRS duration &gt; 120 msec, or bradycardia&#xD;
             defined by sinus rate &lt; 50 bps&#xD;
&#xD;
          -  Use of QT-prolonging medication, renal or hepatic disease, structural heart disease or&#xD;
             left ventricular dysfunction&#xD;
&#xD;
          -  Any symptomatic or asymptomatic arrhythmia excluding sinus arrhythmia and bradycardia&#xD;
             ≥ 50 bps.&#xD;
&#xD;
          -  Laboratory abnormalities in the parameters listed below:&#xD;
&#xD;
               1. Absolute neutrophil count ≤ 1,000 cells/μl&#xD;
&#xD;
               2. Hemoglobin &lt; 11 gm/dL&#xD;
&#xD;
               3. Platelet count &lt; 125,000 cells/μl&#xD;
&#xD;
               4. Alanine Aminotransferase (ALT) ≥ 1.25 x ULN&#xD;
&#xD;
               5. Aspartate Aminotransferase (AST) ≥ 1.25 x ULN&#xD;
&#xD;
               6. Total bilirubin &gt; 1.0 ULN&#xD;
&#xD;
               7. Creatinine &gt; 1.0 ULN&#xD;
&#xD;
          -  Any vaccination within 14 days prior to 3BNC117 administration&#xD;
&#xD;
          -  Receipt of any therapeutic HIV vaccine in the past&#xD;
&#xD;
          -  Receipt of any monoclonal antibody or HDAC inhibitor of any kind in the past.&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within past 12 weeks, or expected participation during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Romidepsin</keyword>
  <keyword>3BNC117</keyword>
  <keyword>Broadly neutralizing antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

